---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-26-000057"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2026-08-03T20:15:23+00:00"
generated_at: "2026-08-03T20:16:05.363991+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma regains NYSE American listing compliance after $13.6M offering

## Summary
- Received NYSE American letter confirming compliance with continued listing standards; .BC indicator to be removed.
- Resolved deficiencies under Sections 1003(a)(i) and (ii) of the NYSE American Company Guide.
- Compliance achieved after July 2026 underwritten public offering: 17.85M shares + pre-funded warrants, net proceeds ~$13.6M.
- Potential additional $34M gross proceeds from milestone warrants if fully exercised.
- Company believes stockholders' equity now exceeds $4M minimum requirement.

## SEC filing metadata
- accession: 0001837607-26-000057
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2026-08-03T20:15:23+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760726000057/0001837607-26-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760726000057/aeon-20260803x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-26-000057
- JSON: https://secwatch.observer/filing/0001837607-26-000057.json
- Plain text: https://secwatch.observer/filing/0001837607-26-000057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.